Menu

Learn About Us

OS Therapies is a clinical stage cancer immunotherapy company developing new treatments for Osteosarcoma (OS) and other solid tumors.

About Us

OS Therapies (OST) is a clinical stage cancer immunotherapy company focused on the identification, development and commercialization of new treatments for Osteosarcoma (OS) and other solid tumors.

OS Therapies (OST) was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates.
OS Therapies logo
At OST, we are answering the call to develop new treatments, considering there have been no new treatments for OS in over 30 years. OST has expanded the pipeline beyond Osteosarcoma with OST-HER2 into other solid tumors with the same recurrence mechanism of action, including Breast, Esophageal and Lung cancer.

OST-tADC, our second program, is Antibody Drug Conjugate (ADC) platform technology that allows us to target solid tumors in a way that potentially ‘dramatically improves efficacy by delivering more cancer killing drug product with significantly reduced side effects by only releasing the cancer killing drug product in ph-sensitive tumor microenvironments.
Our Goals

Our goal is to bring to market the first new treatment for Osteosarcoma in over 30 years, and deploy that new treatment against other solid tumors, using regulatory and commercialization expertise.

Starting with the most common genetic mutation found in Osteosarcoma, OS Therapies has identified a lead candidate in HER2 Osteosarcoma metastases with a goal of rapid clinical development, regulatory review and approval to allow commercial launch to meet patient needs.

Osteosarcoma
Osteosarcoma (OS)—quite literally "bone cancer"—is an extremely rare cancer that occurs primarily in kids, and affects approximately 1000 people in the U.S. each year. OS is know for its extremely aggressive nature and high rates of recurrence.

Most Osteosarcomas occur in children and young adults. Teens are the most commonly affected age group, but Osteosarcoma can occur at any age. There is significant unmet need for new and more effective treatments for OS. OS Therapies was created to bring to market new treatments.

Learn more
Ready to help?

Join Our Mission

Volunteer to work with OS Therapies today. Help us achieve our goals.
Please let us know if you would be interested in joining our mission to identify and clinically prove new treatments for osteosarcoma. We are located in the Washington Metropolitan area near the NIH, FDA, researchers, capital and a thriving bio-science culture.